Enabling NGS-Based Product Characterization and Biosafety Assays in GxP Environments

This blog post is the first part of a comprehensive two-part series, in which we will examine the regulatory landscape and the requirements associated with the implementation of NGS-based assays in a validated environment.

Next-generation sequencing (NGS) is a well-established analytical technology in biopharmaceutical research and development. Its use is also growing in regulated areas such as product characterization, biosafety testing, and manufacturing.

Originally adopted as a research tool, NGS has evolved to deliver comprehensive, high-resolution molecular insights needed for increasingly complex biotherapeutics. As use has matured, regulatory expectations have evolved in parallel. Authorities have defined clearer frameworks for the application of NGS‑based assays in GxP environments, including recent updates to international guidance such as ICH Q5A(R2). As a result, the industry conversation has shifted from whether sequencing technologies can be used in regulated settings to how they should be applied in a compliant manner.

Against this backdrop, understanding where NGS fits within GxP expectations and what regulators require is essential for biopharmaceutical organizations looking to adopt or expand its use. Genedata Selector® is a GxP-validation-ready platform for NGS data management and analysis, enabling biopharma and biotech organizations to operationalize these guidelines within a compliant and scalable environment for quality control.

Why NGS Aligns with GxP Expectations for Data Integrity and Reproducibility

Regulatory frameworks within GxP environments define strict requirements for how analytical data is generated, processed, and reported in biopharmaceutical workflows. NGS is increasingly valuable because it enables comprehensive molecular analysis within controlled, auditable systems. It can be effectively implemented in GxP settings due to its fully digital output, standardized workflows, and compatibility with validated computerized systems. Compared to manual or paper-based assays, sequencing data can be captured, stored, processed, and reviewed in a structured and systematic manner, in line with ALCOA+ principles. 

A key strength of NGS in GxP environments is its ability to support accurate and reproducible analysis across instruments, laboratories, and studies when implemented within validated computerized systems. Structured sequencing data, combined with defined analysis pipelines, enables consistent generation and interpretation of results over time. This reproducibility, together with complete traceability of samples, data transformations, analysis steps and ownership, is essential for meeting GxP expectations and supporting audit and inspection readiness.

Benefits of NGS for Product Characterization in GxP Environments

NGS delivers comprehensive, consistent, and interpretable sequence-level insights. Compared with traditional analytical methods, it enables more informed quality decisions across the entire development lifecycle—from discovery through manufacturing.  NGS can be deployed within GxP-compliant workflows, supporting product quality and regulatory compliance.

In practice, these benefits are most evident in three areas¹ ²:

1. Replacing or complementing classical biosafety assays
2. Enabling robust characterization of master cell banks and raw materials including plasmids and cell lines
3. Assessment of critical quality attributes (CQAs) such as identity, integrity, and potency of drug products 

NGS Replacing or Complementing Classical Biosafety Assays

Classical biosafety testing approaches, including targeted PCR assays, in vitro infectivity tests, and in vivo animal studies, are primarily designed to detect predefined risks. While these methods remain established and widely used in regulated settings, there is increasing emphasis on reducing reliance on animal studies and, where scientifically justified, replacing or complementing conventional assays with more advanced methods.³ 

NGS offers a complementary approach to biosafety testing by enabling simultaneous screening of a broad range of potential adventitious agents. It improves the sensitivity and comparability of results, while reducing the need for assay combinations and the risk of missing unknown contaminants.  

Beyond its analytical advantages, the adoption of NGS also delivers tangible operational benefits in GxP settings by reducing testing complexity, shortening turnaround times, and lowering overall costs. 

This shift enables a more comprehensive and risk-based approach to biosafety testing, strengthening confidence in product quality and supporting regulatory decision-making. 

NGS Enabling Robust Characterization of Master Cell Banks and Raw Materials

Master cell bank (MCB) testing is a foundational element of biopharmaceutical manufacturing, as it underpins the consistency and quality of all subsequent production batches. In this context, NGS is increasingly used to support cell line characterization by enabling detailed assessment of genetic stability across manufacturing sites over time. 

By providing high-resolution, sequence-based data, NGS enables more consistent and sensitive characterization of drug products and raw materials, including plasmids and cell lines. Compared to traditional methods such as Sanger sequencing or PCR-based identity tests, NGS offers significant improvements to sensitivity, supporting more robust verification of identity, detection of genetic variation, and enhanced control of material quality throughout the product lifecycle.  

Together, these capabilities enable more robust and scalable characterization of cell bank and critical material, strengthening batch consistency while reducing analytical complexity, timelines, and cost in GxP environments. 

The Assessment of CQAs

Beyond master cell bank characterization, NGS plays a critical role in the assessment of selected CQAs of drug products, particularly in the context of cell and gene therapies. In these modalities, where the drug product itself consists of DNA or RNA (e.g., viral vectors, plasmids, or engineered cells), sequence-level characterization is essential to ensure identity, integrity, and potency. 

NGS enables comprehensive molecular characterization by providing high-resolution sequence data that supports verification of transgene identity, detection of low-frequency variants, and assessment of genomic integrity. This level of detail is increasingly required to meet regulatory expectations for the characterization and control of complex biological products. 

Importantly, the combination of short-read and long-read sequencing technologies further enhances these capabilities. Short-read sequencing provides high accuracy and deep coverage for detecting small sequence variants, while long-read sequencing enables direct characterization of constructs integrity such as truncations and fusions. Together, these approaches deliver a more complete and reliable view of product structure and heterogeneity. 

In GxP-compliant workflows, this integrated sequencing approach strengthens confidence in CQA assessment by improving robustness, sensitivity, and comparability across studies. At the same time, it supports more efficient and consolidated analytical strategies, reducing reliance on fragmented testing approaches while enabling more consistent, data-driven quality decisions aligned with regulatory expectations. 

Understanding the Regulatory Landscape for NGS‑Based Assays in GxP Environments 

As NGS is increasingly adopted in regulated biopharmaceutical workflows, regulatory frameworks define how these assays must be designed, validated, and governed to ensure data integrity and analytical reliability. 

Current guidance emphasizes end-to-end control across sequencing workflows, including data handling, analytical rigor, system governance, and computerized system validation (CSV). Key frameworks include ICH Q5A(R2) ⁴, which recognizes NGS as a complementary approach for viral safety evaluation, and FDA 21 CFR Part 11⁵, which defines requirements for electronic records and data integrity.  

While ICH Q5A(R2) requires validation of the full NGS workflow—from wet lab processes through data analysis—it provides limited methodological detail, leaving responsibility for implementation with the individual organization. 

More recently, updates to the European Pharmacopoeia (Ph. Eur. 2.6.41) have clarified how to validate NGS-based assays in a quality control context. These guidelines outline the key steps of the workflow, including sample preparation, sequencing, bioinformatics analysis, and reporting, thereby providing a more practical structure for integration into GxP environments. 

Together, these frameworks establish clear expectations for the validation of the complete NGS workflow as an end-to-end system, combining laboratory processes, computational analysis, and data management. This holistic approach ensures that results reliable, traceable, and suitable for regulatory decision-making within GxP environments. 

Conclusion: From Regulatory Acceptance to Compliant Operation 

NGS is no longer an emerging technology in biopharmaceutical development and manufacturing. Its role in product characterization and biosafety testing is increasingly accepted, and regulatory frameworks have evolved to define clearer expectations for its use in GxP environments ⁶ ⁷ ⁸ . Guidance such as ICH Q5A(R2), together with established data integrity requirements, reflects a shift toward more formalized use of NGS-based assays within regulated workflows. 

With this regulatory foundation in place, the challenge has moved beyond adoption. The focus is now on operating NGS-based assays in a compliant, consistent, and scalable manner. This requires coordinated control across laboratory processes, data handling, and system governance to ensure results remain reliable, traceable, and inspection-ready over time. 

To address these requirements, biopharmaceutical organizations increasingly rely on validated informatics platforms that provide a single source of truth across the NGS workflow. Genedata developed Selector to support validation-ready NGS applications. Built on experience from regulated implementations and close collaboration with industry partners, the platform enables the design and execution of tailored, reliable workflows that meet both project-specific and regulatory requirements. 

The discussion therefore shifts from regulatory context to execution. A follow-up article examines the practical considerations of implementing NGS at scale, including computerized system validation, multi-site workflow management, and validation of both wet lab protocols and bioinformatics pipelines in GxP environments. 

 Learn More 
View part two of this blog series.

Original blog published 12/05/2024. Edited by Craig Blyth, MSc, Marketing Content Creator on 7/7/2026.
 

References